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Autoimmune polyglandular syndrome type 1 (APS1) is a progressive life-threatening illness with no known cure. Current
treatments involve replacement of the hormone deﬁciencies that result from autoimmune destruction of multiple endocrine
organs. We report on a girl whose disease was progressing rapidly until she began on immunosuppressive agents. A healthy 6year-old girl with no remarkable medical history presented with new onset hypocalcemic seizures and primary hypoparathyroidism. Howell-Jolly bodies consistent with autoimmune hyposplenism were also noted. Genetic testing revealed compound
heterozygosity for 2 disease-associated variants in the autoimmune regulator (AIRE) gene. She later developed elevated liver
enzymes, primary adrenal insuﬃciency, and alopecia totalis. Serologic testing revealed antibodies to 21-hydroxylase, intrinsic
factor, and smooth muscle. Hydrocortisone was initiated for adrenal insuﬃciency. Shortly afterwards, her liver enzymes
normalized, and her smooth muscle antibody levels began to decline. Serologic testing performed at age 11 revealed seropositivity
for glutamic acid decarboxylase (GAD) antibodies, antinuclear antibodies, and Sjögren syndrome A (SSA) antibodies. At age 12,
she was given 2 doses of rituximab. Hair loss rapidly progressed to alopecia totalis and then to alopecia universalis, at which time
oral methotrexate treatment was initiated. For the past 7 years while on glucocorticoid and methotrexate treatment, our patient
has displayed normalization of 2 antibodies, a lack of progression to additional autoimmune diseases, and experienced reversal of
alopecia universalis.

1. Introduction
Autoimmune polyglandular syndrome type 1 (APS1), also
known as APECED (autoimmune polyendocrinopathy
candidiasis ectodermal dysplasia), is a rare but serious
disorder associated with progressive autoimmune destruction of multiple endocrine and nonendocrine organs. APS1
has a high mortality rate. The median age at death ranges
from 5 to 34 years, with deaths attributable to endocrinopathies, malignancy, acute hepatitis, and infection [1].
APS1 is caused by biallelic variations of the gene encoding
the autoimmune regulator (AIRE), resulting in dysfunction
of regulatory T cells, impaired immunologic tolerance to

self-antigens with subsequent development of multiple
autoimmune conditions [2]. Immunosuppressive therapies
have been generally reserved for life-threatening features of
APS1. To the best of our knowledge, this is the ﬁrst case
report demonstrating normalization of serology, reversal of
an autoimmune condition, and prolonged lack of progression of autoimmune damage in APS1.

2. Case Report
The patient was a previously healthy 6-year-old girl of
northern European descent whose only concerns had been
enlarged tonsils, chronic constipation, and slow growth. She
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had no other health problems. There was no family history of
endocrine or immunologic diseases. While watching television, she developed a grand mal seizure and became apneic. She was emergently transported to Children’s Mercy
Hospital. Initial physical examination was unremarkable
except for short stature, with weight 20 kg (37.7 percentile)
and height 104.6 cm (less than the 1st percentile). Family
history revealed that the patient’s mother is 162.6 cm tall and
father is 177.8 cm tall; midparental height is 167.7 cm (50th
percentile).
She was found to have a critically low total calcium of
1.1 mmol/L (normal range 2.2–2.5 mmol/L) and a blood
glucose of 3.6 mmol/L (normal range 3.6–6.1 mmol/L). Her
phosphorus was elevated at 3.6 mmol/L (1–1.9 mmol/L), and
magnesium was low at 0.49 mmol/L (0.66–0.94 mmol/L).
Initial iPTH level was low at 7 ng/L (10–89 ng/L), and
subsequent iPTH levels remained low. She was diagnosed
with primary hypoparathyroidism. She received intravenous
calcium chloride and magnesium sulfate. Computed tomography of the head was normal. An extensive endocrine
workup revealed that she had Howell-Jolly bodies consistent
with autoimmune hyposplenism, a condition frequently
seen in APS1 [3]. No other autoimmune deﬁciencies were
noted at that time. Karyotype was 46, XX. Evaluation of 22 q
11 variants was normal. A growth hormone (GH) stimulation test was performed during initial admission. Her peak
GH level was 12.8 ng/mL (normal >10 ng/mL).
With the documentation of two unusual autoimmune
ﬁndings, genetic testing for AIRE gene was performed. The
patient was found to be a compound heterozygote for 2
known disease-causing variants. The ﬁrst was a nucleotide
change of C > T in exon 6 of the AIRE gene resulting in the
substitution of the normal arginine codon with a stop codon
at position 257. This mutation is denoted R257X or
Arg257Term. The second mutation was a 13 base-pair deletion in exon 8, beginning in codon leucine 323 and
resulting in a change from leucine to serine, followed by a
frameshift and premature stop codon 50 residues downstream (denoted c.967 979del13 and p.Leu323SerfsX50).
Thus, she was heterozygous for R257X and c.967 979del13.
Both are common, independently recurring mutations in
APS1 [4]. The 13-base deletion has been published with
various nomenclature (c.965 977del13 or p.Cys322fsX5l).
After testing positive for AIRE gene variants, additional
serologic testing revealed seropositivity for 21-hydroxylase
antibodies (a marker for adrenal autoimmunity) and positivity for intrinsic factor autoantibodies (a marker for
atrophic gastritis). Figure 1(a) shows her positive serology
over time, along with her immunosuppressive medications.
Antibody testing for thyroid disease, type 1 diabetes mellitus,
and celiac disease yielded negative results at that time.
At the age of 6 and a half years, a low-dose ACTH
stimulation test showed a borderline peak cortisol of
433 nmol/L (normal >500 nmol/L). ACTH stimulation
testing was repeated a year later, at which time, she
demonstrated a peak cortisol level of 334 nmol/L, in addition to an elevated renin level. Subsequently, hydrocortisone and ﬂudrocortisone replacement therapy were
initiated. Figure 1(b) shows the number of autoimmune
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conditions over time along with her immunosuppressive
medications.
Because of persistent short stature, she underwent repeat
GH stimulation testing around age 9. Her peak GH level was
11.8 ng/mL, demonstrating GH suﬃciency again. However,
as her height was below the 3rd percentile, growth hormone
therapy was initiated with excellent response. She ultimately
achieved an adult height of 161.5 cm, within the range of her
midparental height.
Her liver enzymes were modestly elevated at this time.
Serologic testing revealed positive smooth muscle antibodies, which are associated with autoimmune hepatitis. At
age 10, she developed hypertension and nephrocalcinosis
and was placed on thiazide diuretics. At the age of 11 years,
serologic testing revealed positive glutamic acid dehydrogenase (GAD), antinuclear antibodies (ANA), and Sjögren
syndrome antibodies (SSA). Her thyroid antibodies have
remained negative throughout her course. Over time, her
smooth muscle antibodies and SSA antibody levels have
gradually normalized (Figure 1(c)).
At age 12 years, she began to develop patches of alopecia
on her scalp, which was distressing to her. We referred her to
rheumatology for aggressive management of her APS1. She
was begun on rituximab, monoclonal antibody therapy
directed at CD20, a B cell epitope. Unfortunately, soon after
she received 2 doses of rituximab, her hair loss progressed
rapidly to alopecia totalis and then progressed to alopecia
universalis.
The patient was referred to pediatric dermatology, who
began with intralesional triamcinolone injections but soon
added oral methotrexate. She was begun on 20 mg weekly,
but this was increased to 25 mg weekly at age 16, which she
continues to date. She was empirically placed on 1 mg folic
acid daily and vitamin B12 with the methotrexate therapy.
Complete hair regrowth was achieved within a year. Figure 2
denotes progressive hair loss (2(a) and 2(b)) followed by hair
regrowth (2(c)). The patient has tolerated the methotrexate
well.
At the age of 15, she was referred to gynecology for
fertility discussion. Periods had been regular throughout,
and gonadotropins were normal. Ovarian antibodies, known
to be nonspeciﬁc, were measured at that time and were
positive. Midcycle LH was 25 IU/L, and FSH was 7.1 IU/L.
Anti-Müllerian hormone (AMH) level was 21.3 pmol/L
(normal range for AMH 7.5–91.8 pmol/L). Six months later,
the AMH level was noted to be 6.9 pmol/L, suggestive of low
ovarian reserve [5, 6]. She then underwent fertility preservation. The procedure was highly successful, with 21 eggs
harvested and stored. Surprisingly, ﬁve months after the
retrieval, AMH levels were found to have normalized at
152.4 pmol/L. Her LH and FSH normalized. Her most recent
LH is 0.5 IU/L, and her LH is 1.9 IUL. Cycles have remained
regular throughout.
At age 18, a bone mineral density study noted focal areas
of severely decreased bone mineral density in the distal
femurs. Plain ﬁlms showed ill-deﬁned lucencies with adjacent sclerosis in the distal femurs, which we attribute to
metaphyseal dysplasia, a rare bone condition previously
described in 2003 in 2 unrelated patients with APS1 [7].
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Figure 1: Timeline of development of autoantibodies (a), autoimmune processes (b), and smooth muscle and SSA antibodies (c) with time
course of known immunosuppressive therapy also shown.

(a)

(b)

(c)

Figure 2: Progression of alopecia: early stages of disease (a), progression of disease (b), improvement in alopecia (c).

Six months later, she suddenly developed profound
hypokalemia, which was thought to relate to apparent
mineralocorticoid excess that has been described in APS1
[2]. This was managed with spironolactone and a reduction
in ﬂudrocortisone. A few weeks later, she experienced

sudden mental status changes. She was seen emergently and
was thought to be in septic shock. Testing for active COVIDinfection was negative, but she had IgG antibodies to
COVID-and met the diagnostic criteria for multisystem
inﬂammatory syndrome in children (MIS-C). She required
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ﬂuids and intensive care support. She recovered uneventfully
from MIS-C, although she remains with elevated brain
natriuretic peptide.
She is currently doing well as a college student at a major
university and undergoes frequent laboratory monitoring.

3. Discussion
Herein, we describe a patient with autoimmune polyglandular syndrome type 1 (APS1) also known as autoimmune polyendocrinopathy candidiasis ectodermal dysplasia
(APECED) with molecularly conﬁrmed disease-causing
variants in the AIRE gene. She was diagnosed at a young age
in the absence of candida infections because of hypoparathyroidism in the presence of Howell-Jolly bodies, suggestive
of autosplenism APS1 [3].
Our patient’s clinical course is to the best of our
knowledge unique. Early in her course, she was developing
seropositivity to various antigens autoimmune conditions at
a consistent rate of nearly one per year (Figure 1(a)). She was
developing autoimmune conditions at nearly the same rate
(Figure 1(b)). In the past 7 years, while receiving physiologic
glucocorticoids and methotrexate therapy, she has not developed any new autoimmune problems. Moreover, her
alopecia universalis has gone into remission, and her smooth
muscle and SSA antibodies have normalized (Figure 1(c)).
We are not aware of any reports in the literature of such
attenuation of APS1.
Current management of APS1 does not generally involve
immunosuppressive therapy. The illness tends to fall in the
realm of endocrinologists rather than immunologists.
Generally, treatment is directed toward replacing the hormones that are deﬁcient as a direct result of the autoimmune
processes. Adrenal disease is treated with glucocorticoid and
mineralocorticoid replacement. Hypoparathyroidism is
treated with oral calcium supplements and activated forms
of vitamin D.
A mouse model of APS1 has been developed [8]. Rituximab and anti-CD4 antibody therapy improve APS1 in
the mouse model [8], but these therapies have not been
translated to humans. We are aware of no active clinical
therapeutic trials.
When immunosuppressive therapies have been used, it is
often in the setting of life-threatening features of APS1. A
recent article outlined the immunosuppressive agents that
have been tried in APS1 patients with severe conditions such
as interstitial lung disease, autoimmune hepatitis, tubulointerstitial nephritis, pure red cell aplasia, and severe
malabsorption [9]. That series included a summary of 13
previously reported patients, and therapies included highdose glucocorticoids, cyclosporine A, mycophenolate
mofetil, rituximab, monoclonal antibodies directed against
CD52, macrolide compounds, and methotrexate [1, 9]. Most
patients received multidrug therapy. Results were mixed.
Only 1 patient, a patient with malabsorption, was treated
with methotrexate. Therapy was combined with high-dose
steroids, and remission in malabsorption was achieved [10].
A handful of other reports exist in which immunosuppressive agents have been used in APS1. Successful
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treatment of ocular keratitis with topical cyclosporine has
been reported in two patients with APS1 [11]. In another
study, 2 of 3 children with autoimmune hepatitis responded
well to glucocorticoids and azathioprine [12]. A young boy
with APS1 underwent a liver transplant and had a reduction
in autoantibodies when he received a regimen of tacrolimus,
prednisone, and mycophenolate mofetil [13].
Patients with isolated autoimmune diseases in the absence of APS1 may experience remissions. Isolated alopecia
totalis can have a variable, relapsing, or remitting course. The
possibility of spontaneous remission exists with this isolated
condition for many years after onset. A similar situation
exists with ovarian failure. A recent meta-analysis evaluating
pregnancies in patients with premature ovarian insuﬃciency
showed a spontaneous pregnancy rate ranging from 2.2 to
14.2% [14].
This study is limited by the diﬃculty in identifying which
immunosuppressive agent may have oﬀered our patient
beneﬁt. The two antibodies that normalized began to decline
after the initiation of hydrocortisone, a known immunosuppressive agent. Fludrocortisone was initiated simultaneously. Although ﬂudrocortisone has signiﬁcant
glucocorticoid eﬀects, those eﬀects are thought to be minimal at physiologic doses. After the 2 doses of rituximab at
age 12, her hair loss acutely accelerated, resulting in a decision to try other forms of immunotherapy. Although hair
loss worsened in close temporal proximity to the rituximab
injections, it is impossible to say whether the rituximab
exacerbated her symptoms or contributed to her later improvement. Based on the timing of the normalization of 2
antibodies prior to beginning on rituximab and methotrexate, it is possible that administration of glucocorticoids
even at physiologic doses may have exerted immune beneﬁts. This case may argue for early and repeated testing for
adrenal insuﬃciency in APS1.
She was switched from a short-acting to a long-acting
glucocorticoid after she achieved her adult height. We
theorized that a long-acting steroid may suppress the immune system more consistently than short-acting ones. She
also received small doses of a plant-derived progesterone,
which is compounded and administered in troche form in
order to titrate the dose. Several studies show that progesterone has glucocorticoid properties [15–17]. To provide
steady release of an additional potentially immunosuppressive agent, we recommended low-dose etonogestrel as
an implant.

4. Conclusions
We describe a patient with molecularly conﬁrmed APS1
with marked attenuation of her seropositivity and autoimmune phenomena and remission in alopecia universalis
while receiving physiologic glucocorticoids and mineralocorticoid, rituximab, and chronic therapy with methotrexate. In APS1, immunosuppressive agents have been used
primarily in patients with life-threatening features such as
autoimmune hepatitis, pulmonary interstitial disease, or
severe malabsorption. As APS1 itself is life-threatening, early
consideration of immunosuppressive agents may be
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warranted. Early testing for adrenal insuﬃciency may justify
early use of glucocorticoids and mineralocorticoids.
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